Carcinoid Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Carcinoid Syndrome (CS) Market Outlook
Thelansis’s “Carcinoid Syndrome (CS)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Carcinoid Syndrome (CS) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Carcinoid
Syndrome (CS) Overview
Carcinoid
syndrome (CS) is a paraneoplastic syndrome caused by the discharge of serotonin
and different substances from well-differentiated neuroendocrine tumors (NETs).
CS is a paraneoplastic syndrome associated with the secretion of around 40
vasoactive hormones, the majority of which are 5-hydroxytryptamine (5-HT). CS
also involves the secretion of histamine (primary gastric NETs), prostaglandins
E and F, kallikrein, and tachykinins. The hallmark symptoms of carcinoid
syndrome are diarrhea and flushing; atypical signs and symptoms can include
wheezing, pellagra, valvular heart disease, telangiectasias, abdominal pain,
and the complications of mesenteric fibrosis, including ureteral obstruction,
bowel ischemia, and bowel obstruction. These symptoms are mediated by the
release of serotonin (5-HT), prostaglandins, kallikrein, histamine, and
tachykinins. These symptoms, as well as the corresponding elevations in lab
tests, are required for the diagnosis of CS. Surgery and medical management are
options for treatment, with somatostatin analogs representing the cornerstone
of therapy.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment